Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (111-120 of 791) with videos related to

Pageof 80
Sort By:
Cancer Journal (Sudbury, Mass.)|November 23, 2007
Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatmentElias Jabbour, Jorge Cortes, Francis Giles, et al.
Expert Review of Hematology|February 25, 2016
Acute myeloid leukemia: advancing clinical trials and promising therapeuticsNaval Daver, Jorge Cortes, Hagop Kantarjian, et al.
Leukemia & Lymphoma|May 3, 2008
Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alphaDushyant Verma, Hagop Kantarjian, Nitin Jain, et al.
Leukemia & Lymphoma|November 6, 2012
Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009Yiming Chen, Haijun Wang, Hagop Kantarjian, et al.
Cancer Control : Journal of the Moffitt Cancer Center|April 16, 2026
Geographic and Demographic Disparities in Receipt of Treatment for Early-Onset Colorectal CancerMeng-Han Tsai, Steven S Coughlin, Jorge Cortes
Blood|December 7, 2007
Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methodsHagop Kantarjian, Charles Schiffer, Dan Jones, et al.
Cancer|January 28, 2004
New agents in acute myeloid leukemia and other myeloid disordersFarhad Ravandi, Hagop Kantarjian, Francis Giles, et al.
American Journal of Hematology|March 5, 2009
Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemiaDushyant Verma, Carmen Fava, Hagop Kantarjian, et al.
Current Oncology Reports|July 20, 2010
Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the "best" therapy?Meetu Agrawal, Ravin J Garg, Hagop Kantarjian, et al.
Nature Reviews. Drug Discovery|February 2, 2011
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyondAlfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes, et al.
Pageof 80

Showing results (111-120 of 791) with videos related to

Sort By:
Pageof 80
Cancer Journal (Sudbury, Mass.)|November 23, 2007
Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatmentElias Jabbour, Jorge Cortes, Francis Giles, et al.
Expert Review of Hematology|February 25, 2016
Acute myeloid leukemia: advancing clinical trials and promising therapeuticsNaval Daver, Jorge Cortes, Hagop Kantarjian, et al.
Leukemia & Lymphoma|May 3, 2008
Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alphaDushyant Verma, Hagop Kantarjian, Nitin Jain, et al.
Leukemia & Lymphoma|November 6, 2012
Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009Yiming Chen, Haijun Wang, Hagop Kantarjian, et al.
Cancer Control : Journal of the Moffitt Cancer Center|April 16, 2026
Geographic and Demographic Disparities in Receipt of Treatment for Early-Onset Colorectal CancerMeng-Han Tsai, Steven S Coughlin, Jorge Cortes
Blood|December 7, 2007
Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methodsHagop Kantarjian, Charles Schiffer, Dan Jones, et al.
Cancer|January 28, 2004
New agents in acute myeloid leukemia and other myeloid disordersFarhad Ravandi, Hagop Kantarjian, Francis Giles, et al.
American Journal of Hematology|March 5, 2009
Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemiaDushyant Verma, Carmen Fava, Hagop Kantarjian, et al.
Current Oncology Reports|July 20, 2010
Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the "best" therapy?Meetu Agrawal, Ravin J Garg, Hagop Kantarjian, et al.
Nature Reviews. Drug Discovery|February 2, 2011
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyondAlfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes, et al.
Pageof 80